Latham & Watkins Advises Immuneering in Upsized Initial Public Offering

A corporate deal team advises the biopharmaceutical company in the offering.

July 30, 2021

Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of US$15 per share, for total gross proceeds of US$112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All of the Class A common stock is being offered by Immuneering. The offering is expected to close on August 3, 2021, subject to customary closing conditions. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its Class A common stock at the initial public offering price less the underwriting discounts and commissions.

Latham & Watkins LLP represents Immuneering in the offering with a corporate deal team led by Boston partner John Chory, New York partner Nathan Ajiashvili and Boston partner Evan Smith, with Chicago associate Jonathan Sarna, New York associate Alexandria Plaia and Chicago associate Omeed Valipour.

The firm also advised on the company’s Series A and Series B financings.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.